Need a Reliable Peptide Supplier? Click HERE!!!SponsoredVisit ↗
Lotiglipron and BAC Water Mix

Lotiglipron Reconstitution Calculator

Enter the amount you want to measure. The vial buttons will highlight which vial strengths create cleaner syringe-unit measurements.

What amount do you need?

Type the target amount, then choose mg or mcg. Example: 2mg or 500mcg.

Work the dose out from body weight

Syringe size:
Possible vial strengths:
Best Match Good Match Usable Harder to Measure

Example Lotiglipron Titration Schedule

ParameterDetails
Phase 1 doses10–180 mg oral once daily
Cycle28–42 days (Phase 1)

Discontinued June 2023: transaminase elevations (some ALT/AST >8× ULN) in 6.6%/6.0% of patients versus 1.6% on placebo. Historical data only.

Possible vial strengths:

What Is It?

Lotiglipron

Oral non-peptide GLP-1 receptor agonist.

Bacteriostatic Water

Sterile water containing a bacteriostatic preservative, commonly used when preparing multi-use research vials.

How To Mix Lotiglipron

1
Clean

Use alcohol swabs to clean the tops of both vials.

2
Draw BAC Water

Draw the selected amount of bacteriostatic water.

3
Inject Slowly

Add the liquid slowly down the side of the vial.

4
Swirl Gently

Do not shake. Swirl gently until dissolved.

5
Store Properly

Store as directed and protect from heat and light.

Best Practices & Common Mistakes

Best Practices

  • Use sterile technique.
  • Protect from light and heat.
  • Store refrigerated when appropriate.
  • Use clean syringe-unit math before measuring.

Common Mistakes

  • Confusing milligrams with milliliters.
  • Choosing an option with awkward decimal units.
  • Using too little liquid for very small measurements.
  • Shaking the vial aggressively.

Lotiglipron Storage & Handling

Lyophilized Powder: −20°C (−4°F) for long-term storage (up to 24 months). Refrigeration 2–8°C (36–46°F) for short-term use (up to ~3 months). Original sealed vial in the freezer is safest.
Reconstituted Solution: 2–8°C (36–46°F), use within ~7–14 days. Keep sealed, avoid light, and do not repeat freeze-thaw cycles.

Frequently Asked Questions

Lotiglipron is not a peptide vial compound; it is an oral small-molecule GLP-1 receptor agonist investigated by Pfizer. A calculator page can still explain concentration math for research solutions, but it should not present lotiglipron as a standard bacteriostatic-water peptide reconstitution product.
Pfizer discontinued lotiglipron after pharmacokinetic data and laboratory findings showed elevated transaminases in clinical studies. Those liver enzyme findings made lotiglipron different from a simple “failed weight-loss pill” story, because the program was stopped before it could become an approved medicine.
Lotiglipron and danuglipron were both Pfizer oral GLP-1 receptor agonist candidates, but they were separate molecules with different development paths. Pfizer stopped lotiglipron first in 2023, while danuglipron continued longer before Pfizer later discontinued that program too.
Lotiglipron’s listed formula is C31H31ClN4O5, with a molecular weight of about 575.1 g/mol, which supports describing it as a small molecule rather than a peptide. That matters because small-molecule solubility, solvent choice, and lab handling are not the same as lyophilized peptide reconstitution.
For research math only, concentration equals compound amount divided by final solution volume. For example, if 10 mg of lotiglipron reference material were dissolved to a final volume of 8 mL, the concentration would be 1.25 mg/mL; a 0.5 mg research aliquot would equal 0.40 mL. This is lab concentration math, not a dosing or administration guide.
Practical takeaway: If your goal involves weight management, metabolic health, recovery, physical performance, cognitive function, appearance, or general well-being, discuss it with a licensed healthcare professional. They can help you evaluate approved, evidence-based options rather than relying on an unapproved or investigational compound. This calculator is intended only for transparent research-reference calculations and does not determine an appropriate amount, recommend use, or replace professional medical guidance.

About the author

Maria Hrabina is a pharmacist and scientific reviewer with a strong interest in peptide science, pharmacology, and emerging therapeutic compounds.

Her work focuses on understanding how peptide-based compounds interact with biological signaling pathways and how they are being investigated across areas such as metabolic health, dermatology, recovery, regenerative research, and pharmaceutical development.

Maria follows research on a broad range of peptides, from compounds used in approved medicines to experimental molecules still being evaluated in laboratory, preclinical, and clinical studies.

Her approach combines scientific curiosity with critical evaluation of evidence. She believes promising mechanisms and early research deserve attention, but should not be presented as established clinical benefits until they are supported by adequate human data.

Her areas of focus include scientific literature review, mechanisms of action, pharmacology, pharmacokinetics, safety, pharmaceutical formulation, and the overall quality of evidence behind peptide-based compounds.

She is particularly interested in the process of translating an experimental molecule into a reliable pharmaceutical product — including compound characterization, purity, stability, formulation, dose selection, safety assessment, and controlled clinical trials.

Maria believes peptide science has significant long-term potential, but that its progress depends on rigorous research, high manufacturing standards, transparent safety data, and responsible scientific communication.

Through her writing, she aims to help readers understand both sides of peptide research: what makes these compounds scientifically promising and what questions remain before their potential can be considered clinically established.

Areas of interest: Peptide Science · Therapeutic Peptides · Peptide Pharmacology · Metabolic Peptides · Cosmetic Peptides · Drug Development · Pharmacokinetics · Drug Safety · Pharmaceutical Formulation · Emerging Therapies · Evidence-Based Medicine

Important: This tool is for informational and research-reference purposes only. Not intended for human or veterinary use.
← All peptides